Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668332 | 0.82 | LMNA (0.48) | HRH1ALDH1A1KCNH2LMNASMN1; SMN2 | |
| SCHEMBL22465226 | 0.82 | LMNA (0.48) | HRH1ALDH1A1KCNH2LMNASMN1; SMN2 | |
| SCHEMBL29090786 | 0.79 | HRH1 (0.56) | HRH1ALDH1A1KCNH2ALOX5APKDM4E | |
| SCHEMBL9671309 | 0.79 | BRD4 (0.55) | HRH1ALDH1A1KCNH2ALOX5APKDM4E | |
| SCHEMBL28381278 | 0.79 | CTSD (0.60) | HRH1ALDH1A1ALOX5APKDM4ESMN1; SMN2 | |
| SCHEMBL8134483 | 0.79 | LMNA (0.48) | ALDH1A1KCNH2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1169953 | 0.78 | LMNA (0.70) | ALDH1A1KDM4ELMNASMN1; SMN2CYP1A2 | |
| SCHEMBL24142608 | 0.78 | HRH1 (0.76) | HRH1ALDH1A1KCNH2ALOX5APKDM4E | |
| SCHEMBL10720315 | 0.78 | HTT (0.59) | HRH1ALDH1A1KCNH2ALOX5APKDM4E | |
| SCHEMBL9730468 | 0.78 | ALOX5AP (0.51) | HRH1ALDH1A1KCNH2ALOX5APKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V (BE) (BE) | 2006-07-13 | — | — | US | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-20 | — | — | US | disclosed |
| US-6924287-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACATICA, N.V. (BE) | 2005-08-02 | — | — | US | disclosed |
| EP-1196408-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-15 | — | — | EP | disclosed |
| EP-1418175-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1196408-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0138034-B1 | Substituted pyrido[1,2-c]imidazo[1,2-a]benzimidazoles, process for their preparation, their use and pharmaceutical preparations containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-29 | — | — | EP | disclosed |
| US-4585775-A | ANTIULCER | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| EP-0138034-A1 | Substituted pyrido[1,2-c]imidazo[1,2-a]benzimidazoles, process for their preparation, their use and pharmaceutical preparations containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885ALDH1A1 1134/4885KCNH2 1071/4885 |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885ALDH1A1 1101/4885KCNH2 1080/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885ALDH1A1 1134/4885KCNH2 1071/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | HRH1 65/4885ALDH1A1 1296/4885KCNH2 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.